Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from China’s National Medical Products Administration (NMPA) for its Category 1 chemical drug KH629, which is intended for the treatment of adult non-alcoholic steatohepatitis (NASH). This development follows the previous approval for clinical trials in the US, which was granted in November of the previous year.
KH629, an in-house developed thyroid hormone beta receptor selective agonist, has demonstrated promising results in preclinical studies, showing good safety and therapeutic effects on NASH. These results suggest that KH629 has strong clinical application potential, positioning it as a candidate for further investigation in the treatment of this increasingly prevalent liver disease.
The clinical trial approval from the NMPA is a significant milestone for Kanghong Pharmaceutical as it progresses in the development of KH629, aiming to provide a new treatment option for patients suffering from NASH.- Flcube.com
